Objective:To evaluate the clinical significance of neoadjuvant immunotherapy combined with chemotherapy in the treatment of larynx preservation in locally advanced hypopharyngeal squamous cell carcinoma. Methods:Patients with locally advanced HPSCC（cT3-T4aN0-N3M0） were eligible. All received 2 cycles of pembrolizumab combined with docetaxel and platinum neoadjuvant induction therapy. After two cycles, the efficacy was evaluated, followed by radical chemoradiotherapy or surgery and adjuvant chemoradiotherapy according to the efficacy. The primary endpoints were objective response rate（ORR） ，larynx-preservation（LP） rate at 3 months post-treatment and the adverse reactions during neoadjuvant therapy. Results:From December 2021 to December 2022, 10 patients with locally advanced HPSCC（cT3-T4aN0-N3M0） were enrolled. After 2 cycles of the neoadjuvant therapy, 2 patients achieved complete response（CR）, 7 patients achieved partial response（PR）, 1 patient was stable disease（SD）, objective response rate（ORR） was 90%, and disease control rate（DCR） was 100%. 5 patients received radical chemoradiotherapy, 5 patients received surgery and adjuvant chemoradiotherapy, four of them received partial laryngectomy and partial hypopharyngeal resection surgery, and one of them received total laryngectomy and partial hypopharyngeal resection surgery. All patients were able to withstand adverse reactions of neoadjuvant therapy and successfully completed the whole treatment of HPSCC without grade 3-4 treatment-related adverse reactions. There was no recurrence or metastasis during 3-18 months of follow-up. 1 patient died of severe pneumonia 3 months after the completion of radical chemoradiotherapy. At 3 months after treatment, the larynx-preservation rate was 80%. Conclusion:Neoadjuvant immunotherapy combined with chemotherapy has good short-term efficacy and the adverse reactions were tolerable. It can improve the larynx-preservation rate of patients with locally advanced HPSCC, thus improving the prognosis and quality of life of patients.
目的：评估新辅助免疫联合化疗在局晚期下咽鳞癌患者喉器官保留治疗中的临床意义。 方法：前瞻性纳入cT3-T4aN0-N3M0下咽鳞癌患者。所有患者接受2周期帕博利珠单抗联合多西他赛加铂类新辅助治疗，2个周期后进行疗效评估，根据疗效行根治性放化疗或手术＋辅助放化疗。主要研究终点包括客观缓解率（ORR），治疗后3个月喉器官保留率及新辅助治疗过程中的不良反应。 结果：从2021年12月至2022年12月共纳入10例T3-T4aN0-N3M0下咽鳞癌患者，2周期新辅助治疗后2例达到了完全缓解（CR），7例达到了部分缓解（PR），1例为疾病稳定（SD），客观缓解率（ORR）为90%，疾病控制率（DCR）为100%。10例患者中，5例行根治性放化疗，5例行手术联合辅助放化疗，手术患者中4例行部分喉及部分下咽切除术，1例行全喉及部分下咽切除术。所有患者均能承受新辅助治疗中的不良反应，顺利完成全程治疗，无3～4级治疗相关不良反应，共随访3～18个月无复发转移，其中1例患者根治性放化疗治疗完成后3个月因重症肺炎死亡。治疗后3个月喉器官保留率达到80%。 结论：新辅助免疫联合化疗近期疗效良好，不良反应可耐受，提高了局晚期下咽鳞癌患者喉器官保留率，进而改善患者预后并提高生存质量。.
Keywords: hypopharyngeal neoplasms; larynx-preservation; neoadjuvant chemotherapy; neoadjuvant immunotherapy.
Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.